Theratechnologies to Present Preliminary Safety and Efficacy

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Montreal , Quebec , Canada , Texas , United States , Chicago , Illinois , American , Christian Marsolais , Julie Schneidermansenior , University Of Texas Md Anderson Cancer Center , Drug Administration , American Society Of Clinical Oncology , Theratechnologies Inc , Department Of Investigational Cancer Therapeutics , Communications Corporate Affairs , American Society , Clinical Oncology , Senior Vice President , Chief Medical Officer , Funda Meric Bernstam , Investigational Cancer Therapeutics , Saturday June , Developmental Therapeutics , Targeted Agents , Tumor Biology , Sudocetaxel Zendusortide , Fast Track , Forward Looking Statements , Looking Statements , Annual Information Form , Julie Schneidermansenior Director , Corporate Affairs , Philippe Dubucsenior Vice President , Chief Financial Officer ,